Dear Board of Directors at Paradigm Biopharma,
Would you mind outlining the deals in the Pharma space that your new consultant has been involved with?
Can you please detail the board discussion that approved the options package for the services rendered?
Who voted for, who voted against??
Can, I ask where & how the new consultants role will differ from Beverley's?
What were the details of the Plexus agreement (was it a flat fee, were there warrants or equity kickers)?
I'll be back with more questions shortly.
Kind regards,
Ann: PAR Appoints Business Development Consultant, page-77
Add PAR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
24.5¢ |
Change
0.005(2.08%) |
Mkt cap ! $85.73M | |||
| Open | High | Low | Value | Volume |
| 24.0¢ | 25.0¢ | 23.0¢ | $180.4K | 746.9K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 4 | 79748 | 24.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 25.0¢ | 22818 | 4 |
View Market Depth
| Last trade - 16.10pm 14/11/2024 (20 minute delay) ? |
| PAR (ASX) Chart |